[Federal Register Volume 85, Number 74 (Thursday, April 16, 2020)]
[Notices]
[Page 21269]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08001]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-629]
Importer of Controlled Substances Application: Mylan
Pharmaceuticals Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturer of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before May 18, 2020.
Such persons may also file a written request for a hearing on the
application on or before May 18, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on March 31, 2020, Mylan Pharmaceuticals Inc., 2898
Manufacturers Road, Greensboro, North Carolina 27406, applied to be
registered as an importer of the following basic class(es) of
controlled substances:
------------------------------------------------------------------------
Controlled Substance Drug code Schedule
------------------------------------------------------------------------
Remifentanil......................... 9739 II
------------------------------------------------------------------------
The company plans to import the above-controlled substance as the
FDA-approved drug product in finished dosage form for commercial
distribution to its customers. Approval of permit applications will
occur only when the registrant's business activity is consistent with
what is authorized under 21 U.S.C. 952(a)(2).
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-08001 Filed 4-15-20; 8:45 am]
BILLING CODE 4410-09-P